N-[2-(1,3-benzodioxol-5-ylamino)-1-(4-methylphenyl)-2-oxoethyl]-2-(1H-indol-3-yl)-N-methylacetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-[2-(1,3-benzodioxol-5-ylamino)-1-(4-methylphenyl)-2-oxoethyl]-2-(1H-indol-3-yl)-N-methylacetamide
• 英文别名: N-(1,3-benzodioxol-5-yl)-2-[[2-(1H-indol-3-yl)acetyl]-methylamino]-2-(4-methylphenyl)acetamide
• 化学式: C₂₇H₂₅N₃O₄
• 分子量: 455.5
• InChiKey: RUHOILKYIGRZSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  83.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Compositions and methods for treating disorders associated with salt or fluid retention
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：EP2671584A2

  公开（公告）日：2013-12-11

  Methods for reducing the risk of or treating a disorder associated with fluid and/or salt retention in a patient are described. The methods include administering to the patient an agent selected from: a) an agent that reduces sodium absorption in the intestine; b) an agent that increases anion secretion in the intestine; or c) an agent that both reduces sodium absorption in the intestine and increases anion secretion in the intestine.

  本文描述了降低患者发生与体液和/或盐潴留有关的疾病的风险或治疗这种疾病的方法。这些方法包括向患者施用选自以下几种的制剂：a) 减少肠道钠吸收的制剂；b) 增加肠道阴离子分泌的制剂；或 c) 既减少肠道钠吸收又增加肠道阴离子分泌的制剂。
• COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：EP2152266A1

  公开（公告）日：2010-02-17
• Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof
  申请人：Verkman Alan

  公开号：US20080319008A1

  公开（公告）日：2008-12-25

  The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., ΔF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.
• Compositions and Methods for Treating Disorders Associated with Salt or Fluid Retention
  申请人：Currie Mark G.

  公开号：US20100215779A1

  公开（公告）日：2010-08-26

  Methods for reducing the risk of or treating a disorder associated with fluid and/or salt retention in a patient are described. The methods include administering to the patient an agent selected from: a) an agent that reduces sodium absorption in the intestine; b) an agent that increases anion secretion in the intestine; or c) an agent that both reduces sodium absorption in the intestine and increases anion secretion in the intestine.
• Compounds Having Activity in Increasing Ion Transport by Mutant-CFTR and Uses Thereof
  申请人：Verkman Alan

  公开号：US20120101143A1

  公开（公告）日：2012-04-26

  The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., DF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.